Thus, more potent, second-generation agents gilteritinib, crenolanib, and quizartinib have been developed and have shown promise in relapsed/refractory FLT3+ AML and appear to remain effective as single-agent therapy [5]. This evidence concerns the gene FLT3 and acute myeloid leukemia.